Viking Therapeutics, Inc. VKTX
We take great care to ensure that the data presented and summarized in this overview for Viking Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VKTX
View all-
Black Rock Inc. New York, NY8.27MShares$554 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.79MShares$522 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.59MShares$241 Million3.55% of portfolio
-
State Street Corp Boston, MA3.33MShares$223 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$156 Million0.02% of portfolio
-
Alliancebernstein L.P. New York, NY1.56MShares$105 Million0.05% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V81.38MShares$92.3 Million0.13% of portfolio
-
Viking Global Investors LP1.09MShares$73.4 Million0.34% of portfolio
-
Voya Investment Management LLC Atlanta, GA1.07MShares$71.6 Million0.1% of portfolio
-
Jpmorgan Chase & CO New York, NY1.04MShares$69.7 Million0.01% of portfolio
Latest Institutional Activity in VKTX
Top Purchases
Top Sells
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at VKTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Greg Zante Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
66,756
-7.45%
|
$4,939,944
$74.87 P/Share
|
|
May 03
2024
|
Greg Zante Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,249
+6.51%
|
$136,996
$4.78 P/Share
|
|
May 01
2024
|
Marianna Mancini Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
281,425
-10.65%
|
$21,951,150
$78.38 P/Share
|
|
May 01
2024
|
Marianna Mancini Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
281,425
+9.65%
|
$1,688,550
$6.33 P/Share
|
|
Mar 27
2024
|
Greg Zante Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,610
-7.42%
|
$1,378,630
$83.34 P/Share
|
|
Mar 27
2024
|
Greg Zante Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+12.39%
|
-
|
|
Mar 27
2024
|
Brian Lian President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
153,948
-6.36%
|
$12,777,684
$83.34 P/Share
|
|
Mar 27
2024
|
Brian Lian President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
221,667
+8.39%
|
-
|
|
Mar 27
2024
|
Marianna Mancini Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,610
-4.37%
|
$1,378,630
$83.34 P/Share
|
|
Mar 27
2024
|
Marianna Mancini Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+7.69%
|
-
|
|
Mar 01
2024
|
Greg Zante Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,093
-9.46%
|
$1,707,905
$85.22 P/Share
|
|
Mar 01
2024
|
Greg Zante Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+12.97%
|
-
|
|
Mar 01
2024
|
Marianna Mancini Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,958
-4.64%
|
$1,441,430
$85.22 P/Share
|
|
Mar 01
2024
|
Marianna Mancini Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+7.97%
|
-
|
|
Mar 01
2024
|
Brian Lian President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
162,815
-6.89%
|
$13,839,275
$85.22 P/Share
|
|
Mar 01
2024
|
Brian Lian President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
221,667
+8.58%
|
-
|
|
Feb 09
2024
|
Brian Lian President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-2.06%
|
$1,305,000
$29.9 P/Share
|
|
Feb 08
2024
|
Brian Lian President & CEO |
SELL
Open market or private sale
|
Direct |
269,079
-2.32%
|
$7,265,133
$27.0 P/Share
|
|
Feb 08
2024
|
Brian Lian President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
189,079
+3.79%
|
$378,158
$2.94 P/Share
|
|
Feb 08
2024
|
Sarah Kathryn Rouan Director |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$700,000
$28.05 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 736K shares |
|---|---|
| Grant, award, or other acquisition | 1.08M shares |
| Open market or private sale | 908K shares |
|---|---|
| Payment of exercise price or tax liability | 768K shares |